Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review

Table 2

Characteristics of the PET studies.

Authors	Indication for exam	Diagnostic criteria			Number of neurogenic lesions evaluated	MPNST diagnosis
		Qualitative analysis	Semiquantitative analysis/SUV cutoff	Calculated SUV	(in brackets NF 1 lesions)	Se	Sp
Ferner et al. [9]	Symptomatic NF	Uptake > liver = malignant	—	Mean SUV	23 (23)	100%	87%
Cardona et al. [10]	Suspicious MPNST	Hypermetabolic area	1.8	Median SUV	25 (15)	100%^*	83%^*
Wegner et al. [11]	Symptomatic NF	—	—	—	13 ( n.a.)	—	—
Brenner et al. [12]	Prediction of MPNST outcome	—	3	Mean SUV	16 (16)	75%	100%
Bensaid et al. [13]	Symptomatic NF	—	Tumour/liver ratio >1.5		49 (49)	100%	86%
Bredella et al. [14]	Symptomatic NF	Uptake > liver = malignant	—	Maximum SUV	47 (47)	95%	72%
Ferner et al. [15]	Symptomatic NF	Uptake > liver and not reduced at 4 hours = malignant	—	Maximum SUV	114 (114)	89%	95%
Fisher et al. [16]	High-risk progression NF	5 point visual scale	2	Maximum SUV	19 (19)	—	—
Karabatsou et al. [17]	Suspicious MPNST	not specified	7	Average and maximal SUV	9 (9)	—	—
Warbey et al. [18]	Symptomatic NF	not specified	3.5 (at 4 hours)	Maximum SUV	85 (85)	97%	87%
Benz et al. [19]	Presurgical evaluation of PNST	—	6.1	Maximum SUV	26 (5)	94%	91%
Moharir et al. [20]	Symptomatic NF	—	>3	Maximum SUV	16 (16)	100%	85%

NF: neurofibromas; MPNSTs: malignant peripheral nerve sheath tumors; PNSTs: peripheral nerve sheath tumors; Se: sensitivity; Sp: specificity; ^*: calculated for all 25 neurogenic tumours (15 tumours were detected in 5 NF1 patients) with semiquantitative analysis.